{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05304962",
            "orgStudyIdInfo": {
                "id": "RGT-419B_01-101"
            },
            "organization": {
                "fullName": "Regor Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer",
            "officialTitle": "First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and With Endocrine Therapy in Subjects With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "fih-study-of-rgt-alone-and-with-endocrine-therapy-in-hr-positive-negative-advanced-metastatic-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-02-24",
            "studyFirstSubmitQcDate": "2022-03-30",
            "studyFirstPostDateStruct": {
                "date": "2022-03-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regor Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer"
            ],
            "keywords": [
                "Breast Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "There will be two study arms opened sequentially to the same patient population. Arm A is RGT-419B alone (singlet). Arm B is RGT-419B + Hormonal Therapy (doublet) and will follow completion of Arm A.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "RGT-419B given alone as monotherapy",
                    "interventionNames": [
                        "Drug: RGT-419B"
                    ]
                },
                {
                    "label": "Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "RGT-419B in combination with Hormonal Therapy",
                    "interventionNames": [
                        "Drug: RGT-419B in combination with hormonal therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RGT-419B",
                    "description": "oral capsules",
                    "armGroupLabels": [
                        "Arm A"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "RGT-419B in combination with hormonal therapy",
                    "description": "RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)",
                    "armGroupLabels": [
                        "Arm B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy",
                    "description": "Number of subjects who have a confirmed DLT at each cohort dose level in singlet and doublet study arms during the first 28-day cycle of RGT-419B treatment.",
                    "timeFrame": "4 weeks (1 cycle)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety & Tolerability - Incidence, Severity, and Causality of all Treatment Emergent Adverse Events (TEAEs)",
                    "description": "Incidence, severity, and causality of all TEAEs will be assessed for all patient participating from Day 1 dosing through end of study.",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cmax",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve (AUC0-t)",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-Time Curve to Infinity (AUC0-inf)",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Plasma Decay Half-Life (t 1/2)",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Time to Reach Maximum Observed Plasma Concentration (Tmax)",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Accumulation rate after multiple doses",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cumulative urinary excretion",
                    "description": "Plasma and urine samples that are being collected for PK assessment may also be used for exploratory metabolite identification",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "Tumor Response assessed by Investigator according to RECIST v1.1",
                    "description": "Tumor response measured by radiologic imaging techniques at baseline and throughout the study",
                    "timeFrame": "through study completion, an average of 1 year"
                },
                {
                    "measure": "QTc Interval - Changes in corrected QT interval",
                    "description": "Number of subjects with a clinically significant increase from baseline in corrected QT (QTc) interval on repeated ECGs during RGT-419B monotherapy.",
                    "timeFrame": "through study completion, an average of 1 year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Symptom Burden",
                    "description": "Change from baseline in symptom burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) from baseline to end of treatment",
                    "timeFrame": "through study completion, an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female \\>/= 18 years old\n2. ECOG Performance Status 0 to 1\n3. Subjects must have histologically or cytologically confirmed diagnosis of ER+, HER2- ABC consistent with ASCO CAP guidelines that is locally advanced and unresectable (Stage III) or metastatic (Stage IV) BC.\n4. Measurable AND evaluable lesions at baseline per RECIST v1.1.\n5. Eligible subjects must meet all of the following criteria:\n\n   * Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4/6i is permitted in the post-surgical adjuvant setting);\n\n     * Subjects must have received therapy for \u22653 months in the MBC setting, or for \u22656 months in the adjuvant setting, prior to progression\n   * Progression after \u22643 lines of prior HT therapy (regardless of whether it is HT alone or in combination with other therapies)\n\n     * Prior HT combination agents, including SERD, SERM or AI, must have received formal approval by regulatory agency.\n   * \u2264 1 prior line of chemotherapy in the metastatic setting\n6. Adequate organ function\n7. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Presence of visceral metastases with severe organ dysfunction as evidence by signs and symptoms, laboratory studies, lymphangitic spread and/or rapid progression of disease\n2. Pregnant or planning to become pregnant\n3. Prior irradiation to \\>25% of the bone marrow and/or inadequate bone marrow function or evidence of clinically significant end-organ damage\n4. Major surgery, chemotherapy, targeted therapy, experimental agents, or radiation within 14-28 days prior to Cycle 1, Day 1\n5. Active, serious medical condition that is not well controlled with locally approved medications allowed by the protocol\n6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joanna Dojillo, MSc",
                    "role": "CONTACT",
                    "phone": "617-315-9070",
                    "email": "joanna.dojillo@regor.com"
                },
                {
                    "name": "Regor Pharmaceuticals Central Office",
                    "role": "CONTACT",
                    "phone": "617-315-9070",
                    "email": "rgt-419b_01-101@regor.com"
                }
            ],
            "locations": [
                {
                    "facility": "Hem-Onc Associates of the Treasure Coast",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Port Saint Lucie",
                    "state": "Florida",
                    "zip": "34952",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.29393,
                        "lon": -80.35033
                    }
                },
                {
                    "facility": "Emory University",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ashley Trumbull, MS",
                            "role": "CONTACT",
                            "phone": "404-778-3969",
                            "email": "Ashley.lynn.trumbull@emory.edu"
                        },
                        {
                            "name": "Kathleen Coleman",
                            "role": "CONTACT",
                            "phone": "404.251.1278",
                            "email": "kathleen.marie.coleman@emory.edu"
                        },
                        {
                            "name": "Kevin Kalinsky, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02142",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amber Newton",
                            "role": "CONTACT",
                            "phone": "617-726-1634",
                            "email": "ANEWTON3@mgh.harvard.edu"
                        },
                        {
                            "name": "Abigail Fessele",
                            "role": "CONTACT",
                            "phone": "(P): 617-724-8305",
                            "email": "afessele@mgh.harvard.edu"
                        },
                        {
                            "name": "Seth Wander, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "New York Cancer and Blood Specialists",
                    "status": "RECRUITING",
                    "city": "Port Jefferson Station",
                    "state": "New York",
                    "zip": "11776",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Laura Parisi, LPN",
                            "role": "CONTACT",
                            "phone": "631-675-5146",
                            "email": "lparisi@nycancer.com"
                        },
                        {
                            "name": "Lauren Gianelli-Bilka, LPN",
                            "role": "CONTACT",
                            "phone": "631-675-5256",
                            "email": "lgianelli@nycancer.com"
                        },
                        {
                            "name": "Richard Zuniga, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.92538,
                        "lon": -73.04733
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M8116",
                    "name": "Estrogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M25769",
                    "name": "Aromatase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11900",
                    "name": "Mitogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M22599",
                    "name": "Estrogen Receptor Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M22597",
                    "name": "Selective Estrogen Receptor Modulators",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}